(Neo)adjuvant erlotinib plus cisplatine verbetert uitkomsten bij stadium III NSCLC

Bronnen:

1. Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018 Jan;19(1):139-148.,Zhong WZ, Wu YL, Chen KN, et al. CTONG 1103: Erlotinib versus Gemcitabine plus Cisplatin as Neo-adjuvant Treatment for Stage IIIA-N2 EGFR-mutation Non-small-cell lung cancer (EMERGING): a Randomised Study. ESMO 2018, abstract LBA48_PR.